Monitoring of PD-L1 expression on circulating immune cells of patients with small cell lung cancer (SCLC) receiving firstline treatment: Prognostic implications

被引：1
|
作者：
Papadaki, M. A. [1 ]
Nikolarakou, M-N. [1 ]
Vorrias, E. [2 ]
Kapetanaki, E-E. [1 ]
Kalapanida, D. [2 ]
Mavroudis, D. [2 ]
Agelaki, S. [2 ]
机构：
[1] UOC Univ Crete, Sch Med, Lab Translat Oncol, Iraklion, Greece
[2] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.181
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
150P
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [31] PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion
    Tseng, Yen-Han
    Ho, Hsiang-Ling
    Lai, Chiung-Ru
    Luo, Yung-Hung
    Tseng, Yen-Chiang
    Whang-Peng, Jacqueline
    Lin, Yi-Hsuan
    Chou, Teh-Ying
    Chen, Yuh-Min
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) : 447 - 453
  • [32] PD-L1 expression by circulating breast cancer cells
    David, Rachel
    LANCET ONCOLOGY, 2015, 16 (07): : E321 - E321
  • [33] PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC).
    Berghoff, Anna Sophie
    Ricken, Gerda
    Wilhelm, Dorothee
    Rajky, Orsolya
    Widhalm, Georg
    Dieckmann, Karin
    Birner, Peter
    Bartsch, Rupert
    Zielinski, Christoph
    Preusser, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
    Lang, C.
    Lantos, A.
    Megyesfalvi, Z.
    Egger, F.
    Hoda, M. A.
    Mosleh, B.
    Klikovits, T.
    Oberndorfer, F.
    Timelthaler, G.
    Ferencz, B.
    Fillinger, J.
    Schwendenwein, A.
    Querner, A. S.
    Boettiger, K.
    Renyi-Vamos, F.
    Hoetzenecker, K.
    Laszlo, V.
    Schelch, K.
    Dome, B.
    ESMO OPEN, 2022, 7 (06)
  • [35] PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (14) : 1667 - 1678
  • [36] PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer
    Woodford, Rachel
    Zhou, Deborah
    Lord, Sarah J.
    Marschner, Ian
    Cooper, Wendy A.
    Lewis, Craig R.
    John, Thomas
    Yang, James Chih-Hsin
    Lee, Chee Khoon
    FUTURE ONCOLOGY, 2022, 18 (14) : 1793 - 1799
  • [37] The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
    Wang, A.
    Wang, H. Y.
    Liu, Y.
    Zhao, M. C.
    Zhang, H. J.
    Lu, Z. Y.
    Fang, Y. C.
    Chen, X. F.
    Liu, G. T.
    EJSO, 2015, 41 (04): : 450 - 456
  • [38] Examination of PD-L1 and MHC Class I Expression in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
    Moore, Margaret
    Mills, Anne
    John, Melson
    Hall, Richard
    Gentzler, Ryan
    Stelow, Edward
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1126 - 1127
  • [39] Examination of PD-L1 and MHC Class I Expression in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
    Moore, Margaret
    Mills, Anne
    John, Melson
    Hall, Richard
    Gentzler, Ryan
    Stelow, Edward
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1126 - 1127
  • [40] Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer
    Cheng, Yuxin
    Wang, Ting
    Lv, Xin
    Li, Rutian
    Yuan, Ling
    Shen, Jie
    Li, Yan
    Yan, Tingting
    Liu, Baorui
    Wang, Lifeng
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 2069 - 2078
12345